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Abstract
What does the future of medicine hold? We asked six researchers to share their most ambitious and optimistic
views of the future, grounded in the present but looking out a decade or more from now to consider what’s
possible. They paint a picture of a connected and data-driven world in which patient value, patient feedback, and
patient empowerment shape a continually learning system that ensures each patient’s experience contributes to
the improved outcome of every patient like them, whether it be through clinical trials, data from consumer devices,
hacking their medical devices, or defining value in thoughtful new ways.
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Healthcare on autopilot: possibilities and pitfalls
for a “machine-learning” health system
Paul Wicks (Fig. 1)
What was the last product you searched for online?
Every aspect of the information presented to you, from
its position on the screen to whether the text was under-
lined, was shaped by thousands of online randomized
controlled experiments and scads of data being proc-
essed in real-time from millions of other customers like
you [1]. Contrast this experience with the last time you
received a healthcare intervention. If a treatment existed
for your problem, then the (very expensive [2]) evidence
for it was generated long ago from a tiny and highly un-
usual [3] group of volunteers who were followed up for
a relatively short time period, with all the data gathered
by the company with most to gain from a positive result
[4], approved in a binary one-time process, and with a
price shrouded in secrecy [5]. Since then, nearly all the
outcome data on the success or failure of the treatment
for every other person like you was either scrawled on
paper in filing cabinets or, most likely, was never written
down in the first place. If the outcome data was stored
electronically, that was probably only for routine
management or reimbursement purposes and extracting
meaning from the “data shadow” is challenging [6].
Consequently, neither you nor your doctor know with
confidence if the treatment they prescribed is really
working for you, the manufacturer does not have much
feedback as to what they could do better, and whoever
paid for it does not know if they got value for money.
This worries me greatly, as it seems like Amazon is
leveraging every drop of data on the planet to feed my
daughter the best suggestion for which episode of Peppa
Pig to watch next, but that the health system has given
me a paper booklet on which to record her health data.
Consumers are going to see more examples of intelli-
gent learning systems in their daily lives. For example,
Tesla cars are electric vehicles packed with sensors and
a wireless transmitter that allows the manufacturer to
understand how their vehicles are being used in real-
time and how they cope with accidents. More recently,
software updates even let software take control of the
vehicle in an “autopilot” mode, the first mainstream
example of a self-driving car [7]. In 2013, when an issue
was identified that could cause the chassis to hit debris
on the road, Tesla was able to issue an “over the air”
software update rather than conduct a full physical recall –
owners woke up the next morning to find their cars
had been automatically updated to adjust the settings
on their suspension overnight. Won’t patients expect
this for their medical devices? Aren’t they right to?
In this Forum article, we look towards the future and
consider how a networked medical environment has the
potential to transform medicine. Hotopf and Narayan
describe the potential for passive data streams from
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smartphones to detect signals in conditions such as epi-
lepsy and depression and to harness novel signals such
as sleep disruption or tone of voice. Basch describes
how patient-reported outcomes, whether gathered in the
clinic or at home through smart devices, could offer a
valuable feedback loop which supplements objective pas-
sive data with actively gathered “just in time” patient
reports to overlay a patient’s reported mood or feelings
of aura. Weatherall highlights the opportunity for clin-
ical trials to leap out of the clinic and on to the screen
of patients’ devices to invite them to consent themselves
and their data into grand distributed experiments echo-
ing the “supercollider leap” of particle physics. Finally,
Gray challenges us to think through the evolving para-
digms of “value” that the future holds, and invites physi-
cians to harness the digital data yield to minimize
variation, prioritize interventions that maximize, and
perhaps even fund all these endeavors by ensuring we
stop paying for things that do not seem to work. In an
accompanying piece from the patient perspective, Omer
describes medicine at the fringes of technology and citi-
zen science with patients taking on the mantle of “health
hackers” and even “cyborgs” as they take control of their
continuous glucose monitors and insulin pumps, repro-
gramming them and creating a community of DIY
developers engaged in a process of open learning that is
already outpacing the traditional medical research
community [8].
Supporting these visions of the future are a number of
assumptions. First, patients themselves must take con-
trol of their health [9], their data [10], and their treat-
ment, building their own learning systems if the status
quo will not satisfy their needs [11]. Today, that is only
true for a subset of engaged and activated patients,
mostly with chronic health conditions, and advances in
behavioral science will need to disseminate the benefits
to hard-to-reach populations. This will require thought-
ful interaction with the built environment, transport
systems, the private sector, and a tapestry of governmen-
tal departments.
Second, this amount of data, evidence, and decision-
making will be unmanageable for humans to process
objectively, recursively, and globally [12]. Implied there-
fore in the rapid, unbiased rationality and continual
improvement of such systems are forms of machine
learning [13], which are being tested in a range of appli-
cations that are currently small-scale, but which might
expand rapidly through connected medical devices. The
challenges there are that new forms of technology often
undergo more scrutiny than the status quo, such as the
high level of media attention surrounding the first Tesla
car to crash on “autopilot mode” compared to the
thousands of accidents that happen every day for cars
under human control [7]. We must also address the fact
that one person’s “data donation” is another person’s
“invasion of privacy” [13]. Trust and transparency will
be essential when a “black box” decision could affect
outcomes (and share prices) on a massive scale [14].
Third, a distributed machine-learning health system
must survive the attempts of entrenched interests to sup-
press it – while a computer system should theoretically
have no conflicts of interest, prejudices, or tendency to
put a positive spin on things, we can see from regulatory
fines, whistleblowing lawsuits, and article retractions in
medical science that a small subset of human actors will
always attempt to stack the deck [15]. Even the most intel-
ligent systems are vulnerable to “garbage in, garbage out”.
Fig. 1 Paul Wicks is Vice President of Innovation at PatientsLikeMe, an
online community for people living with medical conditions.
Specializing in the conduct of clinical research using the Internet, Paul
is responsible for shaping the scientific validity of the PatientsLikeMe
platform and generating insights from personal health data shared by
members. This sharing of online medical data has led to over 70 novel
studies including a patient-led observational trial of lithium in ALS,
digital tools to develop patient-reported outcome measures, a
“dose-response” curve for the benefits of friendship between patients,
and new methods for gaining patient input into clinical trial design.
Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry
(King’s College London) studying cognition and neuroimaging in
rare forms of ALS, and the psychological consequences of Parkinson’s
disease. In 2011, he was awarded MIT Technology Review’s TR35
“Humanitarian of the Year” award and was recognized as a TED
Fellow in 2012
Wicks et al. BMC Medicine  (2016) 14:176 Page 2 of 13
Fourth, such a system is going to have to show results
quickly, which might be supported by pilots with short
iteration cycles with rapid and highly visible results, such
as Google Deepmind’s study of acute kidney injury [16].
By contrast, using an intelligent learning system to
optimize diet and exercise to reduce heart attack risk
over the course of decades will be a much less tractable
problem. Other examples of quick-cycle pilots might
include preventing a seizure with implanted electrodes
[17], correctly classifying anomalies in medical images
[18], or controlling the flow of insulin in patients wear-
ing continuous glucose monitors [11].
Finally, the machine learning health system demands a
new body of medical informatics specialists, composed of
professionals as conversant with medical ethics and
patient ethnography as they are with data visualization
and machine code, and who will be able to protect the
system from spurious data and bad actors while acting as
the human oversight that permits the system to go live
and begin interacting with the public. They will one day
operate as “mission control” for the world’s learning health
systems and their focus must always be “patients first”.
It’s a long shot, but it might just work. If one day my
daughter gets sick, I hope she will be supported and
cared for by a machine-learning intelligent system that
knows so much more than is humanly possible.
Remote assessment: harnessing the digital
revolution for patient benefit
Matthew Hotopf and Vaibhav A. Narayan (Fig. 2 and Fig. 3)
Changing patterns of disease within populations de-
mand new approaches to healthcare. As life expectancy
rises and mortality from cardiovascular disease and can-
cer falls, the proportion of the population living with
other chronic and degenerative conditions has increased
[19]. Amongst these, neuropsychiatric and neurodegener-
ative conditions place the maximum burden on societies
and individuals as measured by years lived with disability,
care-giver burden, and productivity loss [20, 21]. Most
chronic diseases have a fluctuating course, with periods of
good function interspersed with relapses and recurrences,
each of which causes progressive deterioration of the
underlying pathology and functional deficits. Virtually all
chronic diseases share significant comorbidity with de-
pression and other mental disorders, and these comorbidi-
ties amplify disease burden and worsen outcomes [22].
Deteriorating function, however caused, is an obvious
target for secondary prevention.
Current models of disease management typically rely
on patients attending secondary care providers at
arbitrary intervals, with periods of more intensive care
offered when the patient becomes unwell. This problem
is further exacerbated as decreasing resources create
pressure to see more patients in less time at increasingly
infrequent intervals. Patients often feel insufficiently
involved in their care, and healthcare delivery systems
often disadvantage good preventive care: money is
earned treating disease, not keeping people well. Further,
the decisions which clinicians make are often dominated
by lagging indicators of disease with little information or
data to treat proactively. Systematic and reliable patient
reported outcome measurement is rarely attempted and
mental disorders, which contribute so much to disease
burden, are widely overlooked.
Fig. 2 Matthew Hotopf is Director of the South London and Maudsley
NHS Foundation Trust National Institute of Health Research Biomedical
Research Centre (BRC) and Professor of General Hospital Psychiatry at the
Institute of Psychiatry, Psychology and Neuroscience, King’s College
London.He is also an NIHR Senior Investigator.. Matthew was trained in
epidemiology at the London School of Hygiene and Tropical Medicine
and in Psychiatry at the Maudsely. His main area of research is in the
grey area between medicine and psychiatry, exploring the interaction
between mental and physical health, and uses “big data” approaches to
understand this interface better. He has worked extensively in areas
where mental health relates to other walks of life, including occupational
and military health, mental health law, and the wider community.
Matthew also co-leads the Innovative Medicines Initiative RADAR-CNS
(Remote Assessment of Disease And Relapse in CNS disorders) program,
which seeks to use data streams from smartphones and wearables to
assess and predict health states in people with epilepsy, multiple sclerosis
and depression
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In episodic disorders, such as epilepsy, clinicians rely
substantially on patients’ self-report of events, often
recalled over many months, to determine whether current
treatments are effective or can forestall precipitous events
such as seizures. A study in which intracerebral EEG
sensors were used to detect epileptic activity indicated a
stark difference between patients’ self-report and recorded
ictal events [23]. These problems are repeated for most
chronic disease. Not only is this a problem for clinical
practice – where decisions about treatment choice are
often made on sparse and unreliable information, but it
also impacts treatment evaluation in randomized trials –
where, though the process of gathering information may
be more structured, the reliance on self-report adds
considerable “noise” and leads to likely misclassification
errors, reducing statistical power, or worse, causing
misleading results due to information bias.
The digital revolution provides a potential solution to
many of these problems [24]. Two thirds of the UK
population now own a smartphone. Consumer wearable
devices, used to monitor activity and fitness, are becom-
ing increasingly affordable and their uptake is projected
to increase exponentially across all regions of the world
[25]. The sensors available from such devices provide a
window into the lived experiences of patients, giving
information on a patient’s symptoms, behavior and
physiology via measurements of motor activity, circadian
rhythms, sociability, speech, heart rate, galvanic skin
response, and so on. Such passive data streams do not
require the patient to do any more than use the device
and consent for data to be streamed to their healthcare
provider. Passively collected data can be enriched with
active approaches where patients are asked about symp-
toms or daily stresses, or provide a platform for brief
cognitive tasks, often under a challenge paradigm for
increased sensitivity. Linked to suitable patient-owned
health records and to the health provider’s electronic
health record system, such tools would form part of an
infrastructure that could increase patient engagement
and participation in their own healthcare, join physical
and mental health care, and provide a physician with
timely and reliable information required for optimal and
opportune treatment decisions.
The greatest potential for such systems may come
from their ability to predict outcomes and provide
targets for early intervention or prevention. For example,
in recurrent depression, sleep disruption is often a senti-
nel symptom – an indication that a further relapse is
around the corner [26]. Similarly, there is evidence that
daily-life behavioral markers using mobile phone GPS
and usage sensors may predict symptoms of depression
[27]. In multiple sclerosis, subtle changes in symptoms,
such as fatigue, or in motor function or speech prosody,
may indicate an incipient deterioration in clinical state.
If such signals then triggered a change in treatment
which prevented relapse, the benefits could be immense.
Patients would avoid relapse and there would be a
strong value proposition if hospitalizations or more
intense care episodes could be avoided. Healthcare
systems would then move from a “diagnose and treat” to
a “predict and prevent” paradigm.
This vision is at an early stage of development. Numer-
ous building blocks need to be assembled and connected
in order to understand whether this is genuinely feasible
and brings the hoped-for benefits to patients and
healthcare systems. First and foremost, patient involve-
ment and trust is essential. Under what circumstances
would patients be willing to share personal data? Are there
certain data-streams which would be unacceptable to
patients, for example, can GPS data reveal an individual’s
identity? Social media, Internet shopping, supermarket
reward systems, and smart ticketing systems in public
transport have been widely adopted despite reasonable
Fig. 3 Vaibhav Narayan is Senior Director of the Neuroscience
Therapeutic Area, at Janssen R&D, and Head of Neuroscience
Integrated Solutions and Informatics at Janssen Neuroscience. The
Neuroscience Therapeutic Area at Janssen is pioneering a more
personalized and holistic approach to therapeutic intervention
that goes “beyond the pill”, to offer data-driven and science-based
“integrated solutions” for preventing, diagnosing, treating, and
monitoring CNS diseases. Vaibhav’s work is currently focused on
utilizing state-of-the-art informatics methods and digital technologies
for developing markers for early diagnosis, disease progression, drug
response and treatment monitoring in Alzheimer’s and mood, and to
develop novel “point-of-need” tools and technologies for management
of adherence and prediction of relapse in patients with Schizophrenia
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concerns many may have about privacy. Critical to adop-
tion seems to be the perceived utility of digital technolo-
gies – citizens may offset concerns about privacy for the
reward of better, more engaging healthcare. It remains to
be seen whether uses of streamed technology in health
will be perceived as too intrusive, but we anticipate that if
patients own their own data and share it as they choose,
many concerns of privacy may evaporate. A greater threat
to the success of such technologies is probably patient
fatigue – will people remain engaged, willing to wear de-
vices over months or years? Finally, any technology which
draws someone’s attention to health or risk of ill-health
may cause harm. If signals are identified that predict
relapse, they will need sufficient predictive value to be ac-
tionable and inevitably a proportion will be false alarms –
in these circumstances, anxiety may be raised or patients
be exposed to unnecessary interventions. Therefore, the
adoption of such technologies – like all others – requires
a careful assessment of risks and benefits specific to the
use case being entertained.
A second set of challenges is the way in which data
are perceived by healthcare professionals and providers.
In attempting to provide tools that enhance patient
autonomy and ultimately reduce unnecessary clinic visits
or prevent hospitalization, remote assessment technolo-
gies may be seen as a threat – a disrupter of established
practice. However, the intention should never be to
replace a physician’s judgment or limit doctor-patient
interactions. Instead, mobile technologies should seek to
enhance clinical care, which will improve the partner-
ship between doctors and patients. In that context,
getting buy-in from the clinicians, who would be the
ultimate users of patient generated and shared data, is
likely to be crucial. We anticipate that due to the privi-
leged nature of the doctor-patient relationship and the
inherent trust that patients place in their doctors, the
buy-in and recommendation of their doctor will be a cru-
cial factor in a patient’s acceptance of such technologies.
Additionally, the underlying technologies, in which big
data is streamed from devices, integrated with pre-
existing clinical information, and rendered available in
real time with nuanced interpretation, require collabor-
ation between health and life-science sectors with ex-
pertise in the analysis of real-time streamed data, using
learnings from, for example, finance and automotive
industries. If these technologies are to reach the clinic
and meet their potential, they will require careful evalu-
ation in real-world settings. Such evaluation requires
collaboration and input from a variety of industries and
sectors, including digital, life science, academic and
clinical, with strong engagement of the critical stake-
holders – patients, clinical service providers, payers, and
regulators. This is the vision of the Innovative Medicine
Initiative’s Remote Assessment of Disease and Relapse in
Central Nervous System Disorders (RADAR-CNS) pro-
ject, which is a pre-competitive public private partner-
ship co-led by Janssen and King’s College London [28].
The program will, over the next 5 years, test the accept-
ability, utility, and potential benefits of wearable devices
and smartphone technology in multiple sclerosis, epi-
lepsy, and depression.
The future of patient-reported outcomes in med-
ical research and practice
Ethan Basch (Fig. 4)
Patients are frequently asked to report information
about their experiences in medical research and practice.
For example, in clinical trials of arthritis drugs, study
participants might be asked to complete serial question-
naires about their pain and mobility. During receipt of
routine clinical care, patients and their caregivers might
be given a survey about quality of services – asking
whether they felt treated with respect or whether all of
their questions were satisfactorily addressed.
Most of the time, the flow of information is unidirec-
tional – patients report information and it goes into a
black box, perhaps analyzed and used, and perhaps not.
Questionnaire respondents rarely receive feedback about
their own reports or aggregated results combining their
information with that of other patients. Moreover, this
“patient-reported outcome” (PRO) information is rarely
used in real time to guide clinical care. Nevertheless, all
of this is changing rapidly. PROs are being used across
healthcare in novel ways to connect patients with
Fig. 4 Ethan Basch, is a Professor of Medicine and Professor of Public
Health at the University of North Carolina, where he directs the Cancer
Outcomes Research Program. He is an oncologist and outcomes
researcher whose work focuses on bringing the patient voice into clinical
research and practice. Ethan’s research group has developed and
evaluated multiple questionnaire and software systems for patients to
report their own symptoms and side effects, including the PRO-CTCAE
system for the National Cancer Institute, which is coming into use in
cancer drug development trials. He currently leads two US national
studies – developing patient-reported outcome quality metrics for use
in oncology, and integrating PROs into routine cancer care
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providers, help support difficult treatment decisions, and
improve management of symptoms [29, 30]; 10 or even
5 years from now, patients will likely answer questions
throughout their healthcare journey via many vehicles –
mobile devices, computers, phones – and interact with
various automated sensors and wearable devices pouring
information back to their clinical teams and to
researchers. Nurses or pharmacists may receive alerts
for concerning self-reports and message patients back
with advice. Some of this might become automated, with
guideline-recommended care advice sent electronically
to patients who would benefit from it.
When facing difficult choices, the collective experi-
ences of patients like them will be presented to predict
likely outcomes. Therefore, as treatment continues,
progress will be benchmarked against datasets of prior
similar patients. Versions of these models are nascent
but are already happening today. For example, patients
considering surgery or radiation for localized prostate
cancer can use predictive models to view the likelihood
of various outcomes, including disease-free survival or
urinary and erectile dysfunction, based on prior patients
like them [31]. Then, following surgery, they can self-re-
port their urinary and erectile functioning and bench-
mark themselves compared to similar patients to assess
whether they are on a predicted trajectory. Their urolo-
gists see the same information, which is used as a dis-
cussion starting point regarding outcomes and symptom
management.
A recent study that enabled patients to self-report
symptoms during chemotherapy via the web found that
nurses responded to email alerts about patients’ symp-
toms three-quarters of the time [32]. Most responses
involved phone calls to patients to change medications
and educate them about symptom control. Compared to
usual care, patients using this PRO intervention experi-
enced significantly better quality of life, fewer emergency
room visits, and improved survival outcomes.
Numerous systems have been developed for collecting
information from patients, and there is substantial
momentum to integrate these systems into electronic
health record (EHR) software platforms [29]. Several
EHR vendors are creating this functionality within their
own software’s patient portals, with the momentum
being driven by governmental agencies interested to
bring the patient voice into clinical care. Beyond enhan-
cing care itself, there is a broad desire to make such in-
formation a standard component of EHR data to enable
comparative effectiveness analyses that include PROs
[33] and to evaluate quality of care based on symptom
trajectories [34]. In the US, the state of Minnesota is
routinely collecting PRO data for psychiatric, orthopedic,
and oncologic conditions to understand comparative
quality of care delivery based on how patients are feeling
and functioning during or after treatment; across the
UK, PROs are assessed following elective orthopedic and
vascular procedures; and in Ontario, Canada, PROs are
routinely collected via computer kiosks placed in oncol-
ogy offices across the province [35]. Major research
funding agencies have propelled this field forward,
particularly in the advancement of methodology. The
Patient-Centered Outcomes Research Institute (PCORI)
has sponsored meetings and white papers on this topic,
and the Agency for Healthcare Research and Quality has
issued funding announcements specifically to evaluate
the use of PROs in EHRs [36, 37]. Expert panels have
been convened by the National Quality Forum and the
US President’s Cancer Panel to propel this area towards
standardization [38].
However, there are also major barriers. EHRs are not
there yet technically; PRO functionality in EHR patient
portals remains rudimentary, and most patients still do
not use these portals for communication. It is challen-
ging to collect PROs via other interfaces, such as
automated telephone surveys, and then bring that infor-
mation back into the EHR in an easily digestible format.
This sluggish technical progress has stunted efforts to
integrate PROs seamlessly with clinical and research
workflow – if PROs cannot be easily collected and seen
in the EHR, clinicians will not use this information, no
matter how valuable it is; they simply cannot afford the
extra time to use something that is not embedded within
their daily system.
In conclusion, PROs are here to stay. Within the next
few years, research activities will continue to assess
which outcomes should be measured, what metrics to
use, and the technicalities of how to incorporate PROs
into existing workflows with the least inconvenience to
patients and providers. Finally, the difficult task will be
to determine how the information can best be used and
how new models of non-real time communication, auto-
mated disease management, and decision-making can be
fostered by building on information provided by engaged
patients and caregivers.
The future of clinical trials?
James Weatherall (Fig. 5)
There is a growing view that the clinical trials system
is broken [39] or, at the very least, that it carries a high
risk of not being fit for purpose in 10 years’ time. Cost
and complexity are increasing exponentially, and many
trials fail to recruit to target.
Other experimental paradigms have rolled with the
times – for example, the evolution of the study of the
most fundamental constituents of matter, particle phys-
ics. In the first half of the 20th century, key experimen-
tal findings were derived on a laboratory benchtop. The
second half saw the advent of super-colliders –
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gargantuan apparatuses, spanning huge geographical
areas, in order to respond to the ever-increasing need
for higher precision and higher energy. So, what would
a clinical trial look like, were it to move into the
“super-collider league”?
Firstly, trialists will to have to figure out how to accom-
modate the plethora of new data streams that have re-
cently come online. Personal health sensors and wearable
devices offer useful ways to collect contextual per-patient
data in a “stream” rather than at fixed visits, creating the
promise of continuous monitoring and derivation of
“digital biomarkers”. Moreover, consumer and scalable
genomics is poised to be a game-changer when it comes
to precision and truly personalized medicine. In the
future, these and other data streams will become increas-
ingly impossible to ignore, and data scientists will have to
continually reinvent both themselves and their methods to
ensure that they can make scientific sense of them.
The nature of participation in clinical trials is another
rapidly moving area. “e-Patients” are becoming equals to
their physicians when it comes to knowledge of disease
and treatments; they are showing that they may not al-
ways wait for a conventional clinical trial to finish before
analyzing their own outcomes [40]. Further, patients
may use technology and the Internet to optimize their
health status. Therefore, a clinical trial participant could,
in parallel with their trial participation, be exchanging
structured and unstructured data online with others
who have the same condition. They will also be con-
tributing a lot more self-reported information on a
continuous/real-time basis following paradigms such as
experience sampling rather than the filling-in of long
questionnaires [41]. All of this points towards a shift in
clinical trial participation from passive subjects to active
research partners. What is ultimately being assessed in
such trials is the combination of experimental medicine,
technology, and behavioral and peer support to provide
an adaptive health experience for the patient. Further-
more, there is an ever increasing drive to democratize
clinical trial data and results in the public domain, and
on a large scale, as can be seen through initiatives such
as AllTrials and Vivli [42, 43].
The fundamental substrate of clinical trials is also
changing as electronic data capture (EDC) and EHR
systems move ever closer together [44]. As EHR systems
mature and become more interconnected, the need for
specialized EDC systems should dwindle – allowing tri-
als to be increasingly based on data collection in routine
care, with additional measurements added as required
by the study at hand – the Salford Lung Study is such
an example, although it is the first step on a long road
to genuine "pragmatic trials" [45]. In fact, trials should
become a minimally disruptive, temporary augmentation
to ongoing healthcare practice. This provides unparal-
leled longitudinality of data, with EHRs providing data
from years before to years after the study. This accumu-
lating data could be made available in real-time to both
patient and physician, as long as it does not compromise
the scientific conduct of the trial. Furthermore, what if
Fig. 5 Jim Weatherall is Head of the Advanced Analytics Centre
(AAC) at AstraZeneca, a department of approximately 30 clinical and
health data scientists across three countries covering the disciplines
of advanced statistics, scientific computing, and biomedical and
health informatics. A particle physicist by training, Jim spent time as
an academic researcher, before becoming a scientific software
engineer consulting across a range of different industries, including
the life sciences. He has had affiliate staff status at the University of
Manchester since 2012, most recently being appointed as honorary
reader at the University’s Health eResearch Centre. Jim and his team
have introduced a number of innovations into the clinical research
field, in areas such as data and text mining, data visualization, health
technology evaluation, and clinical trial design
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consumer technology is all that is required, foregoing
the need for any standard EHR or EDC system? The
asthma study launched by the Icahn School of Medicine
at Mount Sinai Hospital in New York [46], based on
Apple’s Research Kit [47], recruited over 4000 partici-
pants in its first 3 days [48].
So what does the clinical trial of the future look like?
Here is a vision, based on a set of modular steps, each
with their own challenges and opportunities:
1. The patient (potential participant) is alerted via their
smart device as to clinical studies that are relevant for
them. This is done automatically, via analysis of their
online health record, and tuned to show the studies
which would strike a balance between the best option
for the patient and the most benefit to research.
2. If necessary, patients can have a discussion with
their healthcare professional regarding participation
to ensure that they have fully understood the
implications, benefits, and risks.
3. They enroll via dynamic consent [49] on their device
and receive enrolment information (if relevant)
immediately.
4. Their own online health record is automatically
associated with the trial’s “virtual database”, joining
other participants, but without having to create a de
novo data store. Their record includes their full
genome sequence, enabling in-depth characterization
and personalization.
5. They attend a screening visit to confirm eligibility
and receive a randomization code, medications, and
tech devices for continuous monitoring.
6. There are relatively few study visits after screening,
with medications being regularly delivered to
convenient collection locations and patients
self-monitoring wherever possible.
7. Throughout the study, the patient receives regular
updates on their health/disease status, as well as
information about how the overall study is progressing.
8. On completion of the study, the patient receives a
full report, including a personal recommendation.
For instance, it could be that it would be best for
them to stay on the experimental treatment as part
of a long-term follow-up.
In conclusion, there are multiple directions in which
clinical trials may be headed in the future, yet accurately
predicting which will have gained the most traction in 10
years’ time is nigh-on impossible. Technology will come
and go, as recent review studies have shown [14]; however,
the best and most adaptable will survive and go on to de-
fine the future of biomedical measurement. Data scientists
will understand how to make sense of heterogeneous data
streams. Patients will become increasingly empowered and
Fig. 6 Sir Muir Gray is Consultant in Public Health at Oxford
University Hospitals NHS Trust, and a Visiting Professor in Knowledge
Management in the Nuffield Department of Surgery. He has been
awarded both a CBE and a Knighthood for services to the NHS. Sir
Gray entered the Public Health Service by joining the City of Oxford
Health Department in 1972. The first phase of his professional career
focused on disease prevention, and he also developed a local, then
national programme of work to promote health in old age, at a time
before the implications of population ageing had been recognised.
Based on work in Oxford he developed a number of national
initiatives, particularly designed to prevent hypothermia, publishing
a Fabian Society report on the relationship between housing and
poverty and the excess winter deaths, many from hypothermia, that
took place in the UK. He was appointed to the board of the Anchor
Housing Association and helped develop their Staying Put
campaign. He has alsodeveloped all the screening programmes in
the NHS, for pregnant women, children, adults and older people for
example offering men aged 65 screening for abdominal aortic
aneurysm and, for both men and women, screening for colorectal
cancer. Working on the principle that the delivery of clean clear
knowledge was analogous to the provision of clean clear water he
saw the organisation and delivery of knowledge as a public health
service, for example developing NHS Choices (www.nhs.uk), and
setting up the Centre for Evidence Based Medicine in Oxford. During
this period he was appointed as the Chief Knowledge Officer of the
NHS. Sir Gray is now working with both NHS England and Public
Health England to bring about a transformation of care with the aim
of increasing value for both populations and individuals
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proactive research partners in ever more decentralized,
virtualized, and flexible trial platforms. Amidst all this, the
one certainty is that trials do have to roll with the times
and evolve towards their own “super-collider” status.
Education and training for value-based medicine
Muir Gray (Fig. 6)
The medical profession, much like all other human
organizations, is constantly evolving, and it is now entering
a new paradigm – the value-based paradigm. Over the past
50 years, the medical profession has played a major role in
the paradigm of scientific medicine, namely medicine in
which research has created remarkable opportunities in the
treatment of disease –from transplantation to hip replace-
ment. As part of this paradigm, the profession has also
played a significant role in managing services and institu-
tions to ensure that the research evidence was put into
practice and that the quality of service continually im-
proves. Progress has been highly significant, yet, three main
issues remain to be dealt with by science and management.
The first of these is unwarranted variation, namely
variation that cannot be explained by need or patient
preference, as revealed by the NHS Atlases of Variation
[50] based on the Dartmouth Atlas of Variation in the
United States. These unwarranted variations in access,
quality, investment, and outcome revealed two other
issues: (1) overuse of lower value interventions, which
always results in a waste of resources and often in unin-
tended harm to patients, and (2) underuse of high value
interventions, which always leads to failure to achieve
good outcomes and often to inequity when it occurs in
groups defined by age, ethnicity, or social class.
The appreciation of these problems, combined with the
dramatic stimulus of the global financial collapse, has led to
a new paradigm of medical practice – the value paradigm.
The value paradigm – the doctor as creator of value for
populations and individuals
When acting as a manager of resources, the doctor is
responsible for the quality and safety of the service deliv-
ered to the patients who use it. Quality and safety and,
increasingly, cost are the key factors in the paradigm of
scientific medicine, with the doctor expected to take
explicit responsibility for the management of the service
in which they work, as well as being responsible for
providing a good service for individual patients.
However, the three problems outlined above – un-
warranted variation, overuse, and underuse – are only
revealed when clinical activity is related to the popula-
tion served and not just to the patients treated. The
reasons for this are, partly, that there is highly variable
referral to specialist services except for relatively simple
health problems such as a fractured neck of femur or
an acute myocardial infarction, and that, as revealed by
the Dartmouth Atlas of Variation and the research related
to it, cultures of clinical practice developed leading to
unwarranted variation at each end of the scale, whereby
clinicians operating at the higher rates and those operating
at the lower rates of intervention both believe they are
doing the right thing.
It is now clear that it is helpful to think of three types
of value, two of which relate to the population (allocative
and technical) and the third to the individual (personal-
ized value).
 Allocative value is determined by how well the
resources are allocated to the different groups
within the population, aiming to reach what
economists call “the point of indifference”, namely
the allocation at which it would not be possible to
get any more value for the population by shifting a
single pound from one budget to another.
Fig. 7 Personalization of medicine relating to a patient’s needs and values. Re-used with permission from Offox Press [51]
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 Technical value relates outcomes to costs, the costs
being considered not only in terms of money but
also in terms of carbon and the time of clinicians
and patients. This is a broader concept than
efficiency because it takes into account not only the
efficiency with which the service treats those
patients that use it, but also raises issues about
whether or not the patients being treated are those
who would benefit most from the service in the
population and whether there is over- or underuse.
 Personalized value relates the outcome to the values
of the individual patient, namely the problem that
was bothering them most, the value they place on a
good or bad outcome, and the value they place on
either taking or avoiding risks.
In the new paradigm, therefore, we are seeing the de-
velopment of managerial skills as well as that of skills re-
quired for the practice of a population and personalized
medicine. The term “personalized medicine” has become
increasingly commonly used, with personalization relat-
ing to a patient’s needs and values (Fig. 7) [51].
The term “precision medicine” is also now used by
many as a subset of personalized medicine. Personalized
medicine is not a new concept, it has always been essen-
tial to make a personalized decision for an operation like
a knee replacement, whereas precision medicine is a
term used when genomic information is employed either
in diagnosis (molecular diagnostics) or the choice of
treatment (pharmacogenomics).
Here are the five key activities that clinicians need to
develop to increase value (Fig. 8) [51]:
1. Ensuring that every individual receives high personal
value by providing people with full information
about the risks and benefits of the intervention
being offered.
2. Shifting resource from budgets where there is
evidence from unwarranted variation of overuse or
lower value to budgets for populations in which
there is evidence of underuse and inequity.
3. Ensuring that those people in the population who
will derive most value from a service reach that
service.
4. Implementation of high value innovation funded by
reduced spending on lower value interventions for
the population.
5. Increased rates of higher value intervention, e.g.,
helping a higher proportion of people die well at
home funded by reduced spending on lower value
care in hospital in that population.
Sometimes, a new paradigm completely displaces an
old one, although it may embrace and envelop it; for ex-
ample, Einstein’s paradigm shift was certainly disruptive,
but Newtonian physics still serves many useful purposes.
The paradigm of value-based medicine embraces and
Fig. 8 Key activities that clinicians need to develop to increase value.
Re-used with permission from Offox Press [51]
Fig. 9 Point of optimality is reached beyond which additional resources do not cause any additional increase in value, and the reverse takes place.
Re-used with permission from Offox Press [51]
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envelops that of scientific medicine. It is vitally import-
ant that we continue to do research, make decisions on
research-based evidence, and improve quality – this is
necessary but not sufficient to meet the challenges to be
faced in the decades to come. The medical profession
will need to act as the stewards of the health service, as
emphasized by the Academy of Medical Royal Colleges
on their report “Protecting Resources, Promoting Value”
[52]. The act of stewardship is to hold something in trust
for the next generation and implies that clinicians
cannot simply focus on what is best for their specialty.
The medical profession, as a whole, must take responsi-
bility for stewardship, and yet individual clinicians must
still take responsibility for individuals; nevertheless, as it
appears, this creates an difficult tension. However, a
means to reconcile the two apparently segregated issues
of population values and personal values seems to be
emerging.
The stimulus for change is arising not only from the
global collapse and its consequences, but also as a result
of the growing awareness of the problems of overuse
and the harm that inevitably ensues. As more resources
are invested in a population, the benefits may flatten but
will, in fact, increase in direct proportion. Thus, as first
discussed by Avedis Donabedian in 1966 [53], a point of
optimality is reached beyond which additional resources
do not cause any additional increase in value and, in
fact, the reverse takes place (Fig. 9) [51].
As more resources are invested in the population, the
types of patients offered treatment will change, with less
severely affected patients being offered treatment. The
less severely affected the patient is, the smaller the
benefit they will perceive, but both the probability and
magnitude of harm remain constant (Fig. 10) [51].
Population medicine is the new role for the medical
profession. Thus, as those responsible for value, the indi-
vidual clinician and the medical profession as a whole
share the same goal, namely that of optimizing value.
What is also emerging with this focus on personalization
and the developments in digital technology that allow the
traditional functions of the doctor, such as information-
giving, to be carried out digitally, is that patients highly
value empathy and compassion in a clinician as well as the
obvious expectations of technical excellence.
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